ANGLE PLC: Revolutionizing Cancer Treatment with Dual Analysis of CTC-DNA and ctDNA

ANGLE plc (AIM:AGL)(OTCQX:ANPCY), a world-leading liquid biopsy company, has announced breakthrough results from its dual analysis of circulating tumor DNA (ctDNA) and CTC-DNA using Illumina's technology platform. The study, conducted on 27 lung cancer patients, demonstrated that 100% of untreated patients and 90% of treated patients had cancer mutations identified exclusively in CTC-DNA, not found in ctDNA from the same blood sample. This finding highlights the potential for the Parsortix system to identify key variants (DNA mutations) missed by other approaches, helping to guide treatment decisions.

The research utilized Illumina's customized 79-gene lung cancer panel with NGS completed on the Illumina NextSeq 2000 platform. The dual analysis approach found twice as many mutations compared to single-analyte testing, potentially providing more comprehensive biomarkers for treatment guidance. Following these positive results, ANGLE has been invited to present their findings at an EACR-Illumina webinar on February 6, 2025.

Aligning the Parsortix system with Illumina's NGS instruments and gene panels benefits both ANGLE and Illumina, as well as their respective customers. This collaboration enables Illumina's customers to introduce Parsortix-based CTC analysis for DNA dual analysis NGS sequencing, allowing for the analysis of large gene panels and cancer-specific mutations. The webinar is the first joint marketing initiative for ANGLE and Illumina, increasing visibility and credibility for both companies and their respective products.

The new DNA sample-to-answer molecular solution combining CTC and ctDNA analysis is expected to be a driver of product and pharma services sales. By providing a unique insight into the progression of each patient's cancer, this approach has the potential to improve treatment guidance and patient outcomes in lung cancer patients. The ability to analyze both CTC-DNA and ctDNA from the same blood sample could enable clinicians to track the clonal evolution of a patient's cancer, monitor treatment response, and highlight drug resistance mechanisms earlier, allowing for timely adjustments in treatment strategies.



In conclusion, ANGLE PLC's dual analysis of CTC-DNA and ctDNA using Illumina's assay platform has the potential to revolutionize cancer treatment by providing a more comprehensive profile of a patient's cancer. This approach could lead to improved treatment guidance and patient outcomes, as well as expanded product offerings and enhanced biomarker discovery for both ANGLE and Illumina. As the first joint marketing initiative between the two companies, this collaboration marks an exciting step forward in the field of liquid biopsy research and clinical drug discovery and development.